Abstract
Author(s): Jignesh Shah, Deepika Bhat, Dilip Maheshwari
As increased angiogenesis has been related with the progression of Ovarian cancer, Metastatic colorectal cancer (mCRC), Metastatic renal cell, Glioblastoma multiforme, Non squamous non-small cell lung cancer (NSCLC), number of anti-angiogenic agents have been investigated or are currently in development, as a potential treatment options for patients with advanced disease. Bevacizumab, a recombinant monoclonal antibody having targeted action against vascular endothelial growth factor (VEGF) has gained European Medical Agency (EMA) approval for treating the cancer mentioned above in combination with chemotherapeutic agents. Globally the incidence/new cases for the cancer is about 14.1 millions, 8.2 million cancer deaths and about five year prevalence was around 32.6 million cancers individuals that were above 15 years. Globocan 2012 indicates that the number might increase to 19.3 million new cancer cases by 2025. In India there are about 1.1 million new cancer cases, 682,830 cancer deaths and five-year prevalence was around 1.8 million individuals having or diagnosed with cancer. There are very few targeted therapies that are available for treating such type of cancer and Avastin is one of innovator product are available to patients. But due to its high cost it become difficult for patients use the drug for treatment purpose. So there arises a need to bring a quality generic version of the innovator drug to benefit Indian patients. Many leading Indian companies are striving to develop or manufacture such lifesaving drugs to make it available to Indian patients. A systemic literature survey was carried out to identify data available for in such type of cancer and to foster the strategy with a vision to bring global availability of the quality product to Indian patients.
